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Abstract
Objectives: One reason that women over age 50 report avoiding cervical screening is increased discomfort postmen-
opause. This study aimed to explore the acceptability of human papillomavirus testing on clinician-collected vaginal
samples without a speculum (‘non-speculum’) for cervical screening among older women.
Methods: Thirty-eight women in England aged 50–64 with a range of cervical screening experience (‘up-to-date’ n¼ 17,
‘overdue screening’ n¼ 18, ‘never screened’ n¼ 3) were identified via a recruitment agency. Women participated in
focus groups or interviews about the potential for using clinician-collected samples without a speculum. Discussions
were analysed using Framework Analysis.
Results: The two main themes identified were women’s perceptions of the speculum and attitudes towards non-
speculum screening. Many women reported negative experiences with the speculum, including increased pain after
the menopause. Women generally had positive attitudes towards non-speculum clinician sampling and felt it would be a
less intrusive option, but expressed concern that it could be less accurate than screening with a speculum. Women who
were ‘up-to-date’ preferred conventional screening, while overdue and never screened women welcomed the option to
be screened without a speculum.
Conclusions: Human papillomavirus testing on non-speculum clinician-collected vaginal samples could be an acceptable
alternative cervical screening method for older women. Offering this approach could increase screening uptake in older
women who find conventional cervical screening to be less acceptable with ageing or the menopause.
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Introduction
Almost half of cervical cancer deaths in the UK occur
in women over age 65.1 Most of these occur in women
who were not adequately screened when aged 50–64,2
yet cervical cancer screening coverage amongst women
in this ‘older’ age band has been falling.3 Over a fifth of
women aged 55–64 have not been screened in the last
five years.4 While numerous studies have explored rea-
sons for cervical screening non-attendance,5–8 few of
these have explored barriers to attendance specifically
in older women. A recent review of existing evidence
suggests that older women cite embarrassment, an
absence of symptoms, fear of pain and bad experiences
(including difficulties with the smear-taker accessing
the cervix), as reasons for avoiding screening.9
Difficulties with cervical access and discomfort may
be due to vulvovaginal atrophy,10 which is thought to
affect around half of all postmenopausal women.11
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This could make inserting a speculum and taking a
sample more painful than prior to the menopause.
Widespread dislike of the speculum has been
reported among non-attenders,6 and almost a third of
women aged 50–64 report that cervical screening has
become painful with age.12 Given the high cervical
cancer mortality rates among older women, and falling
screening uptake, it has been argued that changes to the
cervical screening programme should be made to
accommodate the needs of older women.13
Human papillomavirus (HPV) causes almost all cer-
vical cancers.14 HPV-based screening offers greater
protection against invasive cancer than cytological
screening15 and will be the primary cervical screening
test in England from 2019.16 An additional benefit of
HPV testing is that it enables alternative sampling
methods, which could appeal to non-attenders and
help increase uptake. HPV self-sampling is one such
approach that has generated widespread interest.
Numerous studies have shown that HPV self-
sampling can increase screening uptake among non-
attenders;17 however, women consistently worry
about not taking a good-quality sample,18 and that
samples might get contaminated or lost in the post.19
They may also miss the opportunity to discuss related
concerns with a health professional at the time of
screening.19 Because HPV testing on self-samples has
lower specificity (for detecting high-grade cervical
lesions) than clinician-taken samples (with a specu-
lum),20 it is mainly considered as an approach for
non-attenders.
HPV testing on clinician-collected vaginal samples
taken without a speculum is another possibility. This
might appeal to older women who want the reassur-
ance of a clinician-collected sample, without the dis-
comfort of a speculum. Unlike self-sampling, the
dialogue between the woman and sample-taker would
be maintained. This study assessed the acceptability of
non-speculum HPV testing for cervical screening in
older women, using qualitative methods.
Methods
Participants
Women aged 50–64 eligible for cervical screening were
enrolled by an external recruitment agency, Saros
(www.sarosresearch.com). Interested individuals com-
pleted an online questionnaire, which assessed their
suitability for the study. Women with a previous
cancer diagnosis or hysterectomy (i.e. not eligible for
cervical screening) were excluded. In order to explore
attitudes within specific population subgroups, women
from a range of socio-economic status groups and with
different cervical screening histories were sought: ‘up-
to-date’ (screened within the last 5 years), ‘overdue
screening’ (last screen >5 years ago) and ‘never
screened’. A purposive sampling frame was determined
a priori, taking into account the scope and design of the
study.21,22 We planned to recruit two groups of ‘up-to-
date’ and two groups of ‘overdue’ women. By conduct-
ing discussions with these groups separately, we hoped
to encourage women who were overdue to talk more
freely about their screening decisions, without fear of
judgement from women who attended regularly. We
anticipated that recruiting ‘never screened’ women
would be more challenging, and therefore planned
only one group for this screening history. The recruit-
ment agency was commissioned to enrol eligible
women into the study until our target numbers for
each group were met.
Data collection
The study was approved by the University College
London (UCL) Research Ethics Committee (ref:
0496/013). Data collection took place January to
February 2017. Four focus groups were conducted at
UCL, each with eight women. Two groups comprised
women who were ‘up-to-date’ with screening, and two
comprised women who were ‘overdue screening’. The
recruitment agency struggled to recruit ‘never screened’
women, and so widened their search area beyond
London to the whole of England. Three women meet-
ing the criteria were identified, and agreed to partici-
pate. As this was not considered enough to run a focus
group and women were based in different areas of
England, these women participated in interviews,
either face-to-face (n¼ 1) or by telephone (n¼ 2). A
further three women were identified as ‘never screened’
and agreed to participate in face-to-face interviews,
however, once these interviews began, it became clear
that these women had in fact been screened. Two of
these three women were subsequently reclassified as
‘overdue screening’ and one as ‘up-to-date’.
Focus groups and interviews were moderated by
MF, assisted by an additional researcher. After provid-
ing informed consent for the study, participants com-
pleted a short demographic questionnaire assessing
age, marital status, work status, education, religion,
ethnicity, cervical screening history (time since last cer-
vical screening test and missed screening rounds),
future cervical screening intentions and awareness of
HPV. A topic guide was developed for the focus
groups and interviews. This first explored previous
experiences of cervical screening and the speculum
examination. Two example plastic speculums
(PuraspecTM in sizes small and medium) were shown
to stimulate discussion about the speculum. The con-
cept of non-speculum clinician sampling was
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introduced and discussed, with prompts to assess
women’s concerns and perceived benefits of this
method, their willingness to undertake this test and
their confidence in the results. Finally, HPV self-
sampling was described and an example sampler
(Copan FLOQSwabTM) was shown. Women were
then prompted to discuss their attitudes towards this
method. While attitudes to self-sampling were not the
main focus of the study, self-sampling was discussed
for comparison with an alternative approach to cervi-
cal screening. Open-ended questions were used
throughout the focus groups and interviews, to explore
attitudes in-depth. Focus groups and interviews were
recorded and transcribed verbatim by a transcription
company, Devon Transcription (www.devontranscrip
tion.co.uk). Focus groups lasted between 68 and 78
minutes, and interviews between 26 and 36 minutes.
Data analysis
Data were analysed using Framework Analysis, which
aims to summarize data using themed matrices, so that
comparisons and contrasts may be made across and
within cases (i.e. each focus group and each interview
formed a case).21 Two researchers (MF and LM) ini-
tially read and re-read each of the transcripts to famil-
iarize themselves with the data. They then
independently coded the transcripts line by line. Next,
they shared and discussed their codes. These codes were
used to develop a coding framework, which aimed to
capture overarching themes in the data. A matrix was
created to collate examples of data which illustrated
each theme. Themes were then described and explained
using illustrative quotes from the data.
Results
Sample characteristics
Thirty-eight women took part in the study, 32 in focus
groups and 6 in interviews. Table 1 shows the sample’s
demographic characteristics. The mean age was 55
(range 50–64), the majority of women were White
British, and half had a degree or equivalent level of
education. Three quarters were employed part-time or
full-time. Just over half said they had always partici-
pated regularly in cervical screening and the majority
intended to attend their next cervical screening when
invited. Just over half of the women had heard of
HPV (54%).
The main themes, reflecting the topic guide, were
women’s perceptions of the speculum and attitudes
towards non-speculum testing. These themes and
their subthemes are described below. Women also dis-
cussed their attitudes to HPV self-sampling and these
largely reflected previous qualitative studies of HPV
self-sampling. As no novel themes arose here, and
this was not a primary aim of the study, we have
included these findings as supplementary material
only, available online.
Perceptions of the speculum
Women’s discussions about their perceptions of the
speculum comprised two subthemes: (1) Experience of
the speculum and (2) perceived benefits of the
speculum.
Experience of the speculum. Although one of the three
‘never screened’ women had never heard of the specu-
lum, most other women were familiar with the term
‘speculum’ and knew that it was part of the equipment
used for cervical screening. However, some women,
even those who were ‘up-to-date’ with screening, had
never seen a speculum before and several were unaware
what it was used for (i.e. to open the walls of the
vagina):
P5: I had no idea what they looked like.
P7: No, I had no idea. I didn’t know they opened.
(Group 1, ‘up-to-date’)
Table 1. Participants’ demographic characteristics.






Less than five years ago 21 (55)
More than five years ago 11 (29)
Never screened 2 (5)
Don’t know 4 (11)
Ethnicity
White British 27 (71)
Other White background 4 (11)
Asian background 1 (3)
Black background (African/Caribbean/other black) 3 (8)
Mixed ethnic background 3 (8)
Highest level of education
GCSEs or equivalent 8 (21)
A-level or equivalent 10 (26)
Degree or equivalent 19 (50)
Other 1 (3)
Employment status
Employed full time 10 (26)
Employed part time 19 (50)
Unemployed 9 (24)
Numbers reflect data gathered in participant questionnaires.
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Many women described not knowing that the speculum
could be plastic and described only being familiar with
the metal speculum, for which there was widespread
dislike. They described it as looking ‘scary’ and
‘Victorian’, and feeling ‘cold’, ‘intrusive’ and ‘undigni-
fied’. For one of the ‘never screened’ women, the spec-
ulum was what put her off attending, following a
painful failed attempt to insert it: It was just very. . .
very cold, this instrument, and just unable to go in and
I just thought if he doesn’t stop. . . it was really hurting
and I was telling him it was hurting but he wouldn’t stop
and I then went to push his hand away because it was
really hurting [followed later by]. It wasn’t an experi-
ence I wanted to repeat, so I didn’t (Telephone interview
1, ‘never screened’).
Several women described (unprompted) how the
speculum had become more painful postmenopause,
and the consequences of this varied, with some saying
they would be unlikely to return for screening as a
result. This discussion arose in both focus groups
with ‘overdue screening’ women and in one of the
groups with ‘up-to-date’ women:
P8: About five years, the doctors have wanted me to have
a smear test, so I finally went about a month ago, I only
let my doctor do it, female doctor because she is really
nice, I didn’t want the nurse, and she just put it in and I
screamed and just couldn’t do it because it was really
tight and dry. So she gave me oestrogen tablets
Mod: Oh like a pessary. Is it a pessary?
P8: Yes.
P8: I had a tablet form, because you get a gel tablet and I
wanted the tablet. But I started taking them and I
thought. . . I just don’t want to go back to do it, it was
just too painful.
Mod: Yes. So you haven’t been back?
P8: I won’t go back. She didn’t even get it like. . . just up
to about. . . if you say that’s the opening, she got it that
far in, I screamed. It was so painful.
(Group 2, ‘overdue screening’)
Benefits of the speculum. Women perceived several bene-
fits to using the speculum for cervical screening. These
discussions about the benefits of the speculum were
predominantly raised among women who were ‘up-
to-date’. Many believed it was used to get a good
view of the cervix and they felt reassured that the cli-
nician could see the cervix: The idea that occasionally
they do sort of say, ‘Oh, everything looks healthy’,. . .
even if, obviously, there’s always a possibility that the
result will come back and I’ll need another one, but if
it generally looks well, it’s kind of reassuring. (P8,
Group 1, ‘up-to-date’)
The speculum was also described as a way of ensur-
ing it was easy to take the swab and that a sufficient
sample could be collected quickly: ‘It’s allowing them a
full view. . . to see exactly where they need to go and how
much they need, if they’ve taken it from the right area,
and if it’s a sufficient sample being taken’ (P4, Group 3,
‘up-to-date’). One woman described how she felt the
speculum could protect the vagina while the sample
was being taken: ‘At least the one thing with that is
the speculum actually is protecting your insides, and
it’s actually giving them a clear passage’ (P7, Group 4,
‘overdue screening’). Women in both of the ‘up-to-
date’ groups described how the speculum was not a
big issue after childbirth. This was not raised by ‘over-
due screening’ or ‘never screened’ groups.
Attitudes towards non-speculum HPV testing
Views on non-speculum HPV testing differed among
women. Many women, particularly those who were
‘up-to-date’, said they would rather have the speculum
used. Others, particularly in the ‘overdue screening’
group and those who had reported negative experiences
with the speculum, were keen to be screened without a
speculum. Four main sub-themes were identified in
relation to non-speculum HPV testing: (1)
Invasiveness of the sample collection, (2) time to collect
the sample, (3) concerns about accuracy and (4) the
need for information and reassurance.
Invasiveness of the sample collection. The idea of collecting
a sample without using a speculum was generally
described as less invasive, less intimidating and less
likely to be painful than sampling with the speculum:
‘It’s [the speculum] really painful, it opens you up, like
that. That [swab], you are just putting in’ (P8, Group 2,
‘overdue screening’).
One woman mentioned that this method would be
less invasive because fewer things would be inserted
into the vagina, but more women commented that the
size of the sampler relative to the speculum was most
important: ‘To me, anything smaller rather bigger going
in at this point is better . . . It would be great, I think, that
there is a less intrusive way of doing it’ (P4, Group 1,
‘up-to-date’).
Conversely, two women raised concerns about how
non-speculum testing may be more invasive. One
thought the procedure may mean the nurse had to
touch you more to hold you open which would mean
it was actually more invasive than having a speculum
put in: ‘If this thing is like, prising you apart slightly, are
their fingers. . .are they going to be prising you apart with
their fingers?’ (P6, Group 3, ‘up-to-date’). A second
woman worried it might be uncomfortable if the
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clinicians had to ‘poke about’ (Interview 2, ‘never
screened’) to find the correct area.
Time to collect the sample. Several women anticipated
that this procedure would be quicker, because the spec-
ulum was not being inserted first. Others however men-
tioned that it might take longer, because the sample
would be more difficult to collect without the use of a
speculum to see the cervix: ‘It could take longer than a
minute to try and find the right place because she would
have to feel what she’s looking for because she wouldn’t
be able to see, would she?’ (Interview 2, ‘never
screened’).
Concerns about accuracy. Several women raised concerns
about the accuracy of collecting a sample without using
a speculum. There were two key concerns that related
to whether an ‘adequate’ sample could be collected.
The first was that the swab would touch other areas
of the vagina and therefore the sample would collect
cells from the ‘wrong place’ by accident:
P8: Wouldn’t it touch other things on the way to where
it’s going?
Mod: It might do. Would that worry you?
P8: So picking up cells that it doesn’t want on there?
(Group 4, ‘overdue screening’)
Secondly, women worried that the sample-taker would
not be able to see the cervix without a speculum and the
sample might therefore be somewhat ‘hit and miss’.
The potential for a sample to be inaccurate meant a
possibility of having to return for a second appoint-
ment: ‘Would she be able to see what she’s doing?. . .
when she sends the thing off she might not have got it
in the right place and then they call you back’ (Interview
2, ‘up-to-date’). Accuracy concerns were raised by all
women regardless of screening status, but comparisons
relative to cervical cytology, were limited to women
who had attended screening. Among these women,
there was concern that the procedure would not be as
thorough as the current screening method and this led
to women feel unconfident in the results. Some allayed
these concerns saying that they expected clinicians
would be trained in non-speculum sampling.
The need for information and reassurance. Women emphas-
ised that they would want to know that non-speculum
sampling was as effective as current screening, before
agreeing (in theory) that they would have it done: ‘I-I
think I would want quite a bit of information and reas-
surance that it was gonna do the-the-the same, um, job as
the-the old procedure’ (P6, Group 1, ‘up-to-date’).
However, if non-speculum sampling was shown to
be at least as effective as current practice, women were
enthusiastic about this approach: I think that as long as,
like you said, it was proven to be as effective, or even
more so, because generally, when people introduce
change it’s for a number of good reasons. So if it was
proven to be as or more effective, I would 100% go for
that without hesitating, yeah. (P4, Group 1, ‘up-to-
date’)
Some women wanted to know why a ‘deep swab’
(Interview 4, ‘overdue screening’) must be taken, and
why it could not just be a swab from the vaginal
entrance. Others also felt they would want a choice
between speculum and non-speculum sampling.
Discussion
Overall, the findings suggest that non-speculum clini-
cian sampling for cervical screening could be an appeal-
ing option for older women, particularly for those who
may have been put off screening by the speculum exam-
ination. Women generally reported negative percep-
tions of the speculum, particularly increased pain on
insertion since starting the menopause. They felt that
non-speculum sampling could be a less intrusive alter-
native. However, they also raised concerns about this
method, including the potential for increased invasive-
ness, longer time needed to take a sample, and test
accuracy. These issues would need to be addressed in
information materials on non-speculum sampling
methods. We do not believe that these concerns
would persist if the correct information were provided,
but there would clearly be a need to educate practice
nurses and GPs about the benefits and limitations of
this form of cervical screening if it were to be intro-
duced, so that accurate information can be passed on
to patients.
To our knowledge, this is the first study to explore
women’s attitudes towards non-speculum clinician-
sampling for cervical screening. Perspectives were
sought from women from a range of screening back-
grounds in order to compare differences in attitudes
and assess whether this method might promote
uptake in women who are overdue (or have never
attended) for cervical screening. The sample was
diverse in terms of education level and employment
status, so the findings represent a range of views we
might expect among this age group more generally.
Another strength is the focus specifically on older
women, an age group for which data are sparse, yet
cervical cancer mortality rates (in women aged 65þ)
are high.1
We did not provide detailed information about HPV
itself, so discussion was limited to the sample collection
methods only. This meant that women were not told
that they would most likely have to return for a spec-
ulum examination if they tested positive for HPV, nor
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that the sampling method of HPV testing is likely to
influence test accuracy (for detecting cervical disease).
Nor were they told that it was not necessary to visual-
ize, or sample from, the cervix to obtain a good sample
for HPV testing. It is therefore likely that providing
women with more information to allay these concerns
might have resulted in even more positive views on the
non-speculum method.
As with other studies exploring barriers to cervical
screening, women who had never attended screening
were difficult to recruit.5,23 The challenges recruiting
women who have never been screened may be in part
because numbers of never screened women among
those aged 50–64 (excluding those ceased for clinical
reasons) are very low (around 3%4). It is also possible
that women who have never been screened were less
interested in participating in research on a topic of
which they have no experience.
Our finding that some women find insertion of the
speculum to be more painful since starting the meno-
pause, and that this has deterred some from attending
screening, supports research showing that a third of
women aged over 50 have found cervical screening
painful with age.12 Although use of oestrogen creams/
pessaries can relieve discomfort associated with vaginal
atrophy,24 our study demonstrates that for some older
women, there is a strong preference for alternative
methods of screening, which do not require a speculum.
Importantly, the preference for non-speculum clini-
cian-sampling was mostly amongst women overdue
for screening, while women who were up-to-date pre-
ferred conventional screening. This implies that offer-
ing non-speculum sampling would enhance and not
undermine the current screening programme.
Women’s concerns about non-speculum sampling
are similar to those found by acceptability studies for
HPV self-sampling.25 This highlights the importance of
producing information materials for non-speculum cli-
nician sampling, which address concerns about test
accuracy and clearly explains test procedures (including
invasiveness and time). Widespread concern amongst
older women about not taking a good sample for
self-sampling, and the logistics of returning the kit (as
reported in the supporting information), suggests that
non-speculum clinician sampling could be an addition-
al (and potentially more appealing) option to women
who would prefer the reassurance of having a clinician
take the sample.
Conclusion
HPV testing on clinician-collected vaginal samples
without a speculum could be an acceptable method of
cervical screening for older women among whom spec-
ulum examination is a barrier to screening. Clear
descriptions of the tests and procedures involved will
be critical to allay concerns about these alternative
screening methods. Further research into the accuracy
of testing using such samples is warranted.
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